Do you have a background in molecular, biochemical or chemical mechanisms yet are interested in translational medicine?

Are you interested in taking your mechanistic findings rapidly to the bedside in a vibrant clinical research program?

If so, fellowship position supported by the National Institutes of Health and the Prostate Cancer Foundation is available in the laboratory of Dr. Nima Sharifi at the Cleveland Clinic.

Our laboratory focuses on mechanistic discovery to understand the metabolic and molecular mechanisms of androgen synthesis and androgen receptor gain-of-function that lead to resistance to hormonal therapy. Specific areas include:

1) Metabolic and genetic changes required for hormone therapy resistance in prostate cancer and tumor progression

2) Clinical validation in patients and clinical trials using innovative approaches

3) Animal models of advanced prostate cancer for translational and therapeutic studies

4) Identifying targets for the development of new pharmacologic therapies

We discovered the first example of a gain-of-function in a steroid-synthesizing enzyme that enables prostate cancer resistance to hormonal therapy (Chang, et al. Cell. 2013;154:1074-84).

We also recently discovered that abiraterone works by conversion to a more active steroidal metabolite (Li, et al. Nature. 2015;523:347-51), that metabolism is pharmacologically modifiable to optimize therapy (Li, et al. Nature. 2016;533:547-51) and that these events are a class effect of steroidal androgen synthesis inhibitors (Alyamani, et al. Cell Chem Biol. 2017;24:825-32) and genetic determination of metabolite generation (Alyamani, et al. J Clin Invest. 2018;128:3333-40). View a quick summary of these discoveries here: https://www.youtube.com/watch?v=22dFzT4RFno

This position is ideal for an individual with a strong interest in rapid translation of basic mechanistic discoveries to the bedside as this is a principal goal of the Sharifi Laboratory.

For example, we have shown that our discovery of a gain-of-function in a steroid-synthesizing enzyme is a predictive biomarker of poor outcomes after hormonal therapy (Hearn, et al. Lancet Oncol. 2016;17:1435-44; JAMA Oncol. 2018;4:558-62).

We are currently evaluating this biomarker in an active clinical trial and are pursuing similar mechanisms and developing new treatment modalities based on these discoveries.

The position will provide a unique and multidisciplinary exposure to tumor metabolism, molecular oncology, drug development and clinical trials.

Further details are available at: http://www.lerner.ccf.org/cancerbio/sharifi/ and http://newsroom.clevelandclinic.org/?s=sharifi

The ideal candidate has a Ph.D. or A visiting scholar degree in biochemistry, chemistry or molecular biology; has the appropriate expertise in discovery of molecular, biochemical or chemical mechanisms; and is highly driven.

Outstanding verbal and communication skills are required. Interested candidates should send their CV and contact information for 3 references to:

Nima Sharifi, M.D.

Kendrick Family Chair for Prostate Cancer Research

Director, GU Malignancies Research Center

sharifn@ccf.org

院校简介：

克利夫兰医学中心是世界最著名医疗机构之一，机构集合医疗、研究和教育三位一体，提供专业医疗和最新治疗方案的非营利性机构。克利夫兰医学中心始建于1921年2月28日 ，隶属于俄亥俄州一家非营利性公司——克利夫兰临床基金会，并由其经营。

2008年，克利夫兰诊所成为美国第一个、全球第二个签署“联合国全球契约”的医疗服务提供机构。

克利夫兰诊所本部和Fairview医院被指定为Magnet Status医院，这是美国护理资格审查中心授予给优秀护理服务的最高认证。

美国全国科学研究委员会授予克利夫兰诊所“2009-2010年消费者信心选择奖”。

美国道德村协会授予克利夫兰诊所“2009全球最具商业道德企业”称号。